ArticleToxicology research2025
Doxorubicin chitosan-coated ferrite nanoparticles ameliorate hepatic toxicity in Ehrlich solid tumor bearing mice.
Article in Toxicology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Modulation of oxidative stress and P53/PCNA signaling by glucosodiene-loaded nanoferrites (GLONF) in ehrlich solid tumor-induced hepatotoxicity.Scientific reports · 2026Article
- In vivo antitumor activity of doxorubicin loaded on chitosan functionalized PbScientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant tumors, particularly breast malignancies, are leading causes of mortality worldwide due to abnormal cell growth and apoptosis dysregulation, with Ehrlich solid tumors being the most prevalent. This study was designated to study the curative role of load the anticancer drug Doxorubicin (DOX) into chitosan-coated ferrite nanoparticles (CT-MNPs) to form Ferrite/CT/DOX Nano-system against Ehrlich solid tumor (EST) induced hepatotoxicity. A total of 80 female mice were randomly and equally divided into 8 groups (Control; Free Dox; CT-MNPs; DOX-CT-MNPs; EST; EST + Free Dox; EST + CT-MNPs; EST + Dox-CT-MNPs). Current results revealed that EST mice showed a significant elevation in the liver enzyme activities by 200%, thiobarbituric acid (TBAR), proliferating cell nuclear antigen (PCNA) and caspase 3 immunoreactivities. In contrast, total protein, reduced glutathione level (GSH), catalase (CAT) and super oxide dismutase (SOD) activities were markedly reduced by 16.4%, 25.2%, 72.7%, 49%, and 53.15% respectively compared to control mice. Treatment with DOX in free form significantly raises liver oxidative damage, and apoptosis compared to EST untreated mice. Additionally, the treatment with DOX-CT- MNPs improves biochemical and histopathological alterations and decreases apoptosis by 32% compared to free DOX. In conclusion, the loading and encapsulation of DOX into chitosan-coated ferrite nanoparticles ameliorate and minimize the liver toxicity and damage caused by DOX as free form.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.